Dubai, September 2026 – Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo’s next innovation in weight management and type 2 diabetes. The findings were highlighted at Novo’s Capital Markets Day investor briefing.
In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss,
achieving an estimated average weight loss of 12.4%, compared with 9.1%, respectively.
CagriSema also confirmed non-inferior reduction in HbA1c (1.71%) versus tirzepatide (1.67%).
In REDEFINE 9, CagriSema 1.0 mg/1.0 mg provided a weight reduction of 21.0% versus 2.0% for
placebo, and the primary superiority endpoint was met. CagriSema also showed greater
improvements than placebo across prespecified supportive endpoints, including systolic blood
pressure, waist-to-height ratio and fasting lipid profile.
“The results from CagriSema are very encouraging, demonstrating the strong potency of the
combination of semaglutide and cagrilintide. With only 1.0 mg/1.0 mg, CagriSema shows superior weight loss versus tirzepatide 5 mg as well as strong results across obesity and type 2 diabetes,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “CagriSema remains investigational, but these findings strengthen our confidence in its potential, add to the growing evidence for amylin biology and reinforce our ambition to advance the next generation of treatments for obesity and type 2 diabetes.”
Treatment decisions in obesity and type 2 diabetes are often individualised, and not all patients
receive or remain on the highest available dose of current therapies. These data provide important evidence of the potential of CagriSema 1.0 mg/1.0 mg, and expand our understanding of how efficacy, tolerability and dose flexibility may support individualised care.
